Papillary hypertrophy of the upper tarsal conjunctiva during contact lens wear: a 4-month study with ethyl-6-O-decanoyl-glucoside.
OBJECTIVE
We studied the potential effect of ethyl-6-O-decanoyl-glucoside (EDG) on papillary hypertrophy in contact lens wearers who were recruited on the basis of papillary hypertrophy and a long history of contact lens wear. The contact lens care solutions were 0.00025% chlorhexidine acetate (CHX) with or without 0.005% EDG.


METHODS
Nineteen subjects wearing both ionic and non-ionic contact lenses for 6-18 hours used either CHX or CHX+EDG as a cleaning and disinfecting agent. CHX and CHX+EDG was used simultaneously by each subject but in different eyes during two consecutive periods of 8 weeks. Symptoms and signs were recorded at three examinations during the study. The protein content of contact lenses and tryptase activity of tear fluids were measured.


RESULTS
The degree of papillary hypertrophy did not decrease in either the CHX or CHX+EDG groups. Also, there were no differences in protein content of lenses nor tryptase activity of tear fluids in either group. There was a significant correlation between papillary hypertrophy and tryptase activity during the study.


CONCLUSIONS
Despite the earlier finding that EDG prevents development of papillary hypertrophy in contact lens wearers, EDG still cannot reverse established signs of papillary hypertrophy.
Vaahtoranta-Lehtonen
H H
HH
Finnsusp Ltd., Lieto, Finland.
Lehtonen
O P
OP
Harvima
I
I
Peltola
O
O
Nikoskelainen
E
E
D000328:Adult; D043925:Angiogenesis Inducing Agents / Q000378:metabolism; D015415:Biomarkers; D002710:Chlorhexidine / Q000627:therapeutic use; D053818:Chymases; D003228:Conjunctiva / Q000187:drug effects* / Q000473:pathology*; D003229:Conjunctival Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D018639:Contact Lens Solutions / Q000627:therapeutic use; D003262:Contact Lenses, Extended-Wear / Q000009:adverse effects*; D003902:Detergents / Q000627:therapeutic use*; D004202:Disinfectants / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005136:Eye Proteins / Q000378:metabolism; D005143:Eyelids; D005260:Female; D005500:Follow-Up Studies; D005960:Glucosides / Q000627:therapeutic use*; D006801:Humans; D006984:Hypertrophy; D008297:Male; D012697:Serine Endopeptidases / Q000378:metabolism; D013666:Tears / Q000378:metabolism; D053802:Tryptases
D043925:Angiogenesis Inducing Agents; D015415:Biomarkers; D018639:Contact Lens Solutions; D003902:Detergents; D004202:Disinfectants; D005136:Eye Proteins; D005960:Glucosides; C102302:ethyl-6-O-decanoyl glucoside; C042434:tear proteins; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; D053802:Tryptases; D002710:Chlorhexidine